HK1172031A1 - An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase genz 112638 - Google Patents
An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase genz 112638Info
- Publication number
- HK1172031A1 HK1172031A1 HK12112977.8A HK12112977A HK1172031A1 HK 1172031 A1 HK1172031 A1 HK 1172031A1 HK 12112977 A HK12112977 A HK 12112977A HK 1172031 A1 HK1172031 A1 HK 1172031A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- genz
- hemitartrate
- amorphous
- inhibitor
- crystalline form
- Prior art date
Links
- 229960002856 eliglustat Drugs 0.000 title 2
- KUBARPMUNHKBIQ-VTHUDJRQSA-N eliglustat tartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C([C@@H](NC(=O)CCCCCCC)[C@H](O)C=1C=C2OCCOC2=CC=1)N1CCCC1.C([C@@H](NC(=O)CCCCCCC)[C@H](O)C=1C=C2OCCOC2=CC=1)N1CCCC1 KUBARPMUNHKBIQ-VTHUDJRQSA-N 0.000 title 2
- 102000044956 Ceramide glucosyltransferases Human genes 0.000 title 1
- 108091000114 ceramide glucosyltransferase Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
- Saccharide Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26474809P | 2009-11-27 | 2009-11-27 | |
PCT/US2010/057952 WO2011066352A1 (fr) | 2009-11-27 | 2010-11-24 | Forme amorphe et cristalline de l'hémitartrate de genz 112638 au titre d'inhibiteur de la glucosylcéramide synthétase |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1172031A1 true HK1172031A1 (en) | 2013-04-12 |
Family
ID=43431870
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15103822.1A HK1203485A1 (zh) | 2009-11-27 | 2012-12-14 | 在組合療法中治療戈謝病或法布里病的 |
HK12112977.8A HK1172031A1 (en) | 2009-11-27 | 2012-12-14 | An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase genz 112638 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15103822.1A HK1203485A1 (zh) | 2009-11-27 | 2012-12-14 | 在組合療法中治療戈謝病或法布里病的 |
Country Status (41)
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8889127B2 (en) | 2004-07-01 | 2014-11-18 | Icahn School Of Medicine At Mount Sinai | Targeted protein replacement for the treatment of lysosomal storage disorders |
PT3133070T (pt) | 2009-11-27 | 2019-11-11 | Genzyme Corp | Eliglustat (genz 112638) como inibidor de glicosilceramida-sintase para utilização num método de tratamento de doença de fabry ou de gaucher, o método compreendendo ajustar a dose terapêutica individual ao metabolismo do p-450 do doente |
CN103764824B (zh) * | 2011-06-20 | 2018-04-24 | 西奈山医学院 | 粘多糖贮积症和其它溶酶体病症的抗TNF-α疗法 |
HUE051021T2 (hu) | 2011-09-07 | 2021-01-28 | Sinai School Medicine | Ceramidáz és sejtek differenciálódása |
WO2013078413A1 (fr) * | 2011-11-22 | 2013-05-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Modulateurs du stockage lipidique |
WO2013181530A1 (fr) | 2012-06-01 | 2013-12-05 | Icahn School Of Medicine At Mount Sinai | Niveaux de céramide dans le traitement et la prévention d'infections |
ES2739811T3 (es) | 2013-03-14 | 2020-02-04 | Icahn School Med Mount Sinai | Composiciones terapéuticas de ceramidasa ácida y métodos de fabricación y uso de ellas |
MX2016003486A (es) * | 2013-09-20 | 2016-06-28 | Biomarin Pharm Inc | Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades. |
WO2016001885A2 (fr) * | 2014-07-03 | 2016-01-07 | Dr. Reddy’S Laboratories Limited | Forme amorphe d'hémitartrate d'eliglustat |
WO2016166170A1 (fr) | 2015-04-14 | 2016-10-20 | Sandoz Ag | Chlorhydrate d'éliglustat cristallin |
GB201508025D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Fabry disease gene therapy |
AU2016357720A1 (en) | 2015-11-18 | 2018-07-05 | Genzyme Corporation | Biomarker of polycystic kidney disease and uses thereof |
CN107445938B (zh) * | 2016-05-31 | 2020-04-03 | 北京启慧生物医药有限公司 | 依利格鲁司他半酒石酸盐的结晶形式、制备方法和含有所述结晶形式的药用组合物 |
CN106349210A (zh) * | 2016-08-24 | 2017-01-25 | 北京阳光诺和药物研究有限公司 | 一种制备酒石酸艾力骨司坦的方法 |
EP3318277A1 (fr) | 2016-11-04 | 2018-05-09 | Institut du Cerveau et de la Moelle Epiniere-ICM | Inhibiteurs de la synthase de glucosylcéramide pour le traitement de maladies du motoneurone |
WO2018193090A2 (fr) | 2017-04-21 | 2018-10-25 | Amneal Pharmaceuticals Company Gmbh | Procédé de préparation d'hémitartrate d'eliglustat et d'intermédiaires de celui-ci |
WO2018225085A1 (fr) | 2017-06-05 | 2018-12-13 | Cipla Limited | Dispersions solides stables d'hémitartrate d'éliglustat |
JP7045726B2 (ja) | 2017-06-16 | 2022-04-01 | ベータ ファーマ,インコーポレイテッド | N-(2-(2-(ジメチルアミノ)エトキシ)-4-メトキシ-5-((4-(1-メチル-1h-インドール-3-イル)ピリミジン-2-イル)アミノ)フェニル)アクリルアミドおよびその塩の医薬品製剤 |
EP3664798A4 (fr) * | 2017-08-08 | 2021-05-05 | Kashiv Biosciences, LLC | Composition pharmaceutique comprenant de l'éliglustat |
US20200222310A1 (en) * | 2017-08-08 | 2020-07-16 | Kashiv Biosciences, Llc | Pharmaceutical composition comprising eliglustat |
KR20200100697A (ko) | 2017-12-15 | 2020-08-26 | 젠자임 코포레이션 | 고쉐병의 치료 방법 |
US20200316025A1 (en) * | 2017-12-20 | 2020-10-08 | Aizant Drug Research Solutions Private Limited. | Stable amorphous eliglustat premix and process for the preparation thereof |
US11760741B2 (en) | 2018-05-02 | 2023-09-19 | Kashiv Biosciences, Llc | Pro-drugs of eliglustat |
CA3101097A1 (fr) * | 2018-05-27 | 2019-12-05 | Bioasis Technologies Inc. | Traitement de la maladie de gaucher |
CN110878079A (zh) * | 2018-12-31 | 2020-03-13 | 北京启慧生物医药有限公司 | 一种高纯度依利格鲁司他的制备方法 |
CN116120274A (zh) | 2021-11-12 | 2023-05-16 | 曙方(上海)医药科技有限公司 | 依利格鲁司他可药用盐及其晶型 |
Family Cites Families (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8311286D0 (en) | 1983-04-26 | 1983-06-02 | Searle & Co | Carboxyalkyl peptide derivatives |
DE3522475A1 (de) | 1985-06-22 | 1987-01-02 | Kali Chemie Pharma Gmbh | Neue aromatische verbindungen, ihre herstellung und verwendung |
US5041441A (en) | 1988-04-04 | 1991-08-20 | The Regents Of The University Of Michigan | Method of chemotherapy using 1-phenyl-2-decanoylamino-3-morpholino-1-propanol |
ZA929008B (en) | 1991-12-13 | 1993-05-21 | Bristol Myers Squibb Co | Piperazinyl- and piperidinyl-cyclohexanols. |
US5302609A (en) | 1992-12-16 | 1994-04-12 | The Regents Of The University Of Michigan | Treatment of diabetic nephropathy |
US5399567A (en) | 1993-05-13 | 1995-03-21 | Monsanto Company | Method of treating cholera |
JP3778926B2 (ja) | 1993-08-13 | 2006-05-24 | 生化学工業株式会社 | 神経疾患治療剤 |
US6309823B1 (en) | 1993-10-26 | 2001-10-30 | Affymetrix, Inc. | Arrays of nucleic acid probes for analyzing biotransformation genes and methods of using the same |
DK0742789T3 (da) | 1994-02-02 | 2000-11-13 | Liposome Co Inc | Farmaceutisk aktive forbindelser og liposomer og fremgangsmåder til anvendelse af disse |
DE69524592T2 (de) | 1994-06-10 | 2002-07-18 | Seikagaku Kogyo Co Ltd | 2-Acylaminopropanolverbindung und ihre pharmazeutische Zusammensetzung |
FR2734819B1 (fr) | 1995-05-31 | 1997-07-04 | Adir | Nouveaux composes de la piperazine, de la piperidine et de la 1,2,5,6-tetrahydropyridine, leur procede de preparation et les compositions pharmaceutiques les contenant |
US6890949B1 (en) | 1999-07-09 | 2005-05-10 | The Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
WO2001004108A1 (fr) | 1999-07-09 | 2001-01-18 | Regents Of The University Of Michigan | Composes de type amino-ceramide et procedes therapeutiques d'utilisation |
US5916911A (en) | 1995-09-20 | 1999-06-29 | The Regents Of The University Of Michigan | Amino ceramide--like compounds and therapeutic methods of use |
US20030073680A1 (en) | 1995-09-20 | 2003-04-17 | The Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
US6255336B1 (en) | 1995-09-20 | 2001-07-03 | The Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
NO965193L (no) | 1995-12-08 | 1997-06-09 | Seikagaku Kogyo Kk Seikagaku C | Aminalkoholderivat og fremgangsmåte for fremstilling derav |
JP3993908B2 (ja) | 1995-12-08 | 2007-10-17 | 生化学工業株式会社 | アミノアルコール誘導体及び該誘導体の製造方法 |
JP4140984B2 (ja) | 1995-12-20 | 2008-08-27 | 生化学工業株式会社 | 分化誘導作用を有する薬剤 |
US5972928A (en) | 1997-05-21 | 1999-10-26 | Johns Hopkins University | Methods for treatment of conditions associated with lactosylceramide |
JP4036500B2 (ja) | 1997-05-23 | 2008-01-23 | 生化学工業株式会社 | アミノアルコール誘導体及びそれを含有する医薬 |
JP4176170B2 (ja) | 1997-06-06 | 2008-11-05 | 生化学工業株式会社 | アミノアルコール誘導体を含む医薬及び異常増殖性疾患治療薬 |
US6465488B1 (en) | 1997-12-11 | 2002-10-15 | Chancellor, Masters & Scholars Of The University Of Oxford | Inhibition of glycolipid biosynthesis |
AU756008B2 (en) | 1998-07-27 | 2003-01-02 | Johns Hopkins University, The | Methods for treating conditions modulated by lactosylceramide |
US6610703B1 (en) | 1998-12-10 | 2003-08-26 | G.D. Searle & Co. | Method for treatment of glycolipid storage diseases |
MXPA02000296A (es) * | 1999-07-09 | 2004-05-21 | Univ Michigan | Compuestos parecidos a aminoceramida y metodos de uso. |
WO2001051919A2 (fr) * | 2000-01-07 | 2001-07-19 | Transform Pharmaceuticals, Inc. | Formation, identification et analyse a productivites elevees de formes solides diverses |
US6977723B2 (en) | 2000-01-07 | 2005-12-20 | Transform Pharmaceuticals, Inc. | Apparatus and method for high-throughput preparation and spectroscopic classification and characterization of compositions |
SK16372002A3 (sk) | 2000-04-24 | 2003-04-01 | Teva Pharmaceutical Industries Ltd. | Zolpidem hemitartrát |
US6436987B1 (en) | 2000-06-08 | 2002-08-20 | Pfizer Inc. | Crystalline forms of (3S-trans)-2-[3,4-dihydro-4-hydroxy-3-(phenylmethyl)-2H-1-benzopyran-7-yl]-4-(trifluoromethyl)-benzoic acid |
US20040260099A1 (en) | 2001-01-10 | 2004-12-23 | The Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
US20020198240A1 (en) | 2001-01-10 | 2002-12-26 | Shayman James A. | Amino ceramide - like compounds and therapeutic methods of use |
WO2002062777A2 (fr) | 2001-01-10 | 2002-08-15 | The Regents Of The University Of Michigan | Composes du type amino-ceramide et procedes therapeutiques d'utilisation |
US7148251B2 (en) | 2001-01-10 | 2006-12-12 | The Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
MXPA03006294A (es) * | 2001-01-18 | 2003-09-16 | Merck Patent Gmbh | Proteinas de fusion disfuncionales con actividad glucocerebrosidasa. |
ATE554082T1 (de) * | 2001-07-16 | 2012-05-15 | Genzyme Corp | N-acetylsphingosin glukosyltransferase inhibitor |
EP1281755A3 (fr) | 2001-07-31 | 2003-06-18 | Pfizer Products Inc. | Variants du gène humain cyp2d6 |
DK2206702T3 (da) | 2001-08-08 | 2012-02-13 | Tobira Therapeutics Inc | Bicyklisk forbindelse, fremstilling og anvendelse deraf |
US7893101B2 (en) | 2002-03-20 | 2011-02-22 | Celgene Corporation | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
US20060217560A1 (en) | 2002-04-29 | 2006-09-28 | Shayman James A | Amino ceramide-like compounds and therapeutic methods of use |
US6916802B2 (en) | 2002-04-29 | 2005-07-12 | Genzyme Corporation | Amino ceramide-like compounds and therapeutic methods of use |
EP1523310A2 (fr) | 2002-07-09 | 2005-04-20 | The Scripps Research Institute | Procede pour empecher les lesions par ischemie et reperfusion |
US20050032070A1 (en) | 2003-08-05 | 2005-02-10 | Sebastian Raimundo | Polymorphisms in the human gene for CYP2D6 and their use in diagnostic and therapeutic applications |
AR047459A1 (es) * | 2004-01-27 | 2006-01-18 | Synthon Bv | Sales estables de 2-metil-4-(4-metil-1-piperazinil)-10h-tieno[2,3-b][1,5]benzodiazepina (olanzapina) |
US8586610B2 (en) | 2004-09-30 | 2013-11-19 | Vanda Pharmaceuticals, Inc. | Methods for the administration of iloperidone |
BRPI0516001A (pt) | 2004-10-13 | 2008-08-19 | Pharmacia & Upjohn Co Llc | formas cristalinas de 3-[5-cloro-4-[(2, 4-difluorobenzil) óxi]-6-oxopirimidin-1(6h)-il]-n-(2-hidroxietil)-4-metilben zamida |
BRPI0517701A8 (pt) * | 2004-11-10 | 2018-01-23 | Genzyme Corp | métodos de tratamento de diabetes mellitus |
WO2007038676A2 (fr) * | 2005-09-28 | 2007-04-05 | Teva Pharmaceutical Industries Ltd. | Formes polymorphiques de ladostigil tartrate |
WO2007040995A1 (fr) * | 2005-10-03 | 2007-04-12 | Mallinckrodt Inc. | Procédé pour la préparation de polymorphes de zolpidem hémitartrate et tartrate |
MX2007016179A (es) | 2006-04-17 | 2008-03-11 | Teva Pharma | Formas cristalinas de o-desmetilvenlafaxina. |
PL2032134T3 (pl) * | 2006-05-09 | 2015-11-30 | Genzyme Corp | Sposoby leczenia stłuszczeniowej choroby wątroby obejmujące hamowanie syntezy glikosfingolipidów |
KR101271225B1 (ko) | 2006-10-31 | 2013-06-03 | 삼성디스플레이 주식회사 | 발광 다이오드 칩 및 발광 다이오드 광원 모듈의 제조 방법 |
TWI314226B (en) | 2006-12-07 | 2009-09-01 | Ind Tech Res Inst | Piezoelectricity-driving optical lens module |
EP1961765A1 (fr) * | 2006-12-08 | 2008-08-27 | Zealand Pharma A/S | Peptides PTH tronqués à formation cyclique |
MX2009010557A (es) * | 2007-03-30 | 2009-11-19 | Amicus Therapeutics Inc | Metodo para el tratamiento de la enfermedad de fabry que utiliza chaperonas farmacologicas. |
EP2150254A4 (fr) | 2007-04-26 | 2010-11-10 | Amicus Therapeutics Inc | Schémas posologiques pour le traitement de maladies de stockage lysosomal en utilisant des chaperons pharmacologiques |
WO2008150486A2 (fr) * | 2007-05-31 | 2008-12-11 | Genzyme Corporation | Inhibiteurs de glucosylcéramide synthase de type 2-acylaminopropanol |
DE102007029581B4 (de) | 2007-06-26 | 2020-04-09 | GM Global Technology Operations LLC (n. d. Ges. d. Staates Delaware) | Kraftfahrzeugdach und Kraftfahrzeugkarosserie |
EP2227780A4 (fr) | 2008-03-19 | 2011-08-03 | Existence Genetics Llc | Analyse génétique |
WO2009117150A2 (fr) | 2008-03-20 | 2009-09-24 | Genzyme Corporation | Méthode de traitement d’un lupus avec des dérivés de céramide |
ES2760917T3 (es) | 2009-11-27 | 2020-05-18 | Boehringer Ingelheim Int | Tratamiento de pacientes diabéticos genotipificados con inhibidores DPP-IV como la linagliptina |
FR2953139B1 (fr) | 2009-11-27 | 2012-04-13 | Servier Lab | Composition pharmaceutique comprenant un sel de strontium, de la vitamine d et une cyclodextrine |
PT3133070T (pt) | 2009-11-27 | 2019-11-11 | Genzyme Corp | Eliglustat (genz 112638) como inibidor de glicosilceramida-sintase para utilização num método de tratamento de doença de fabry ou de gaucher, o método compreendendo ajustar a dose terapêutica individual ao metabolismo do p-450 do doente |
EA036422B1 (ru) | 2009-11-27 | 2020-11-09 | Адверио Фарма Гмбх | Способ получения метил-{4,6-диамино-2-[1-(2-фторбензил)-1h-пиразоло[3,4-b]пиридин-3-ил]пиримидин-5-ил}метилкарбамата |
US9006270B2 (en) | 2011-06-21 | 2015-04-14 | Novartis Ag | Polymorphs of (S)-pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide |
JO3316B1 (ar) | 2013-05-30 | 2019-03-13 | Lilly Co Eli | مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل |
JP6728842B2 (ja) | 2016-03-24 | 2020-07-22 | オムロン株式会社 | 光学計測装置 |
CN107445938B (zh) | 2016-05-31 | 2020-04-03 | 北京启慧生物医药有限公司 | 依利格鲁司他半酒石酸盐的结晶形式、制备方法和含有所述结晶形式的药用组合物 |
WO2018193090A2 (fr) | 2017-04-21 | 2018-10-25 | Amneal Pharmaceuticals Company Gmbh | Procédé de préparation d'hémitartrate d'eliglustat et d'intermédiaires de celui-ci |
-
2010
- 2010-11-24 PT PT161751177T patent/PT3133070T/pt unknown
- 2010-11-24 AR ARP100104348A patent/AR079152A1/es not_active Application Discontinuation
- 2010-11-24 SI SI201030715T patent/SI2504332T2/sl unknown
- 2010-11-24 HU HUE14164650A patent/HUE029371T2/en unknown
- 2010-11-24 PL PL14164650T patent/PL2796457T3/pl unknown
- 2010-11-24 CN CN201610219151.5A patent/CN105777707B/zh active Active
- 2010-11-24 PT PT141646505T patent/PT2796457T/pt unknown
- 2010-11-24 LT LT16175117T patent/LT3133070T/lt unknown
- 2010-11-24 SI SI201031936T patent/SI3133070T1/sl unknown
- 2010-11-24 KR KR1020207002751A patent/KR20200013105A/ko not_active IP Right Cessation
- 2010-11-24 CA CA3075788A patent/CA3075788C/fr active Active
- 2010-11-24 CN CN202010962663.7A patent/CN112521367B/zh active Active
- 2010-11-24 EP EP16175117.7A patent/EP3133070B1/fr active Active
- 2010-11-24 EA EA201592195A patent/EA029990B1/ru not_active IP Right Cessation
- 2010-11-24 RS RS20140446A patent/RS53503B2/sr unknown
- 2010-11-24 DK DK10785289.9T patent/DK2504332T4/da active
- 2010-11-24 KR KR1020187012588A patent/KR20180049255A/ko not_active IP Right Cessation
- 2010-11-24 SI SI201031252A patent/SI2796457T1/sl unknown
- 2010-11-24 RS RS20191404A patent/RS59543B1/sr unknown
- 2010-11-24 PE PE2012000717A patent/PE20121337A1/es not_active Application Discontinuation
- 2010-11-24 MX MX2012006083A patent/MX358345B/es active IP Right Grant
- 2010-11-24 NZ NZ715108A patent/NZ715108A/en unknown
- 2010-11-24 RS RS20160645A patent/RS54978B1/sr unknown
- 2010-11-24 TW TW106124135A patent/TWI656873B/zh active
- 2010-11-24 LT LTEP14164650.5T patent/LT2796457T/lt unknown
- 2010-11-24 KR KR1020157030851A patent/KR102073207B1/ko active IP Right Grant
- 2010-11-24 ES ES14164650.5T patent/ES2586947T3/es active Active
- 2010-11-24 EP EP14164650.5A patent/EP2796457B1/fr active Active
- 2010-11-24 CN CN201610218210.7A patent/CN105753846B/zh active Active
- 2010-11-24 CA CA2781676A patent/CA2781676C/fr active Active
- 2010-11-24 DK DK16175117T patent/DK3133070T3/da active
- 2010-11-24 PL PL16175117T patent/PL3133070T3/pl unknown
- 2010-11-24 KR KR1020127016671A patent/KR20120115972A/ko active Search and Examination
- 2010-11-24 EP EP21160074.7A patent/EP3896069A1/fr active Pending
- 2010-11-24 JP JP2012541183A patent/JP2013512252A/ja active Pending
- 2010-11-24 EP EP19182732.8A patent/EP3599237B1/fr active Active
- 2010-11-24 MY MYPI2012002297A patent/MY160542A/en unknown
- 2010-11-24 CA CA3140959A patent/CA3140959A1/fr active Pending
- 2010-11-24 PE PE2016002590A patent/PE20171255A1/es unknown
- 2010-11-24 SG SG10201800136QA patent/SG10201800136QA/en unknown
- 2010-11-24 PT PT191827328T patent/PT3599237T/pt unknown
- 2010-11-24 PL PL10785289T patent/PL2504332T5/pl unknown
- 2010-11-24 EP EP10785289.9A patent/EP2504332B2/fr active Active
- 2010-11-24 KR KR1020227040651A patent/KR20220162824A/ko not_active Application Discontinuation
- 2010-11-24 ME MEP-2016-163A patent/ME02477B/fr unknown
- 2010-11-24 TW TW105126084A patent/TWI606827B/zh active
- 2010-11-24 AU AU2010324810A patent/AU2010324810B2/en active Active
- 2010-11-24 ES ES10785289T patent/ES2493940T5/es active Active
- 2010-11-24 ES ES16175117T patent/ES2754398T3/es active Active
- 2010-11-24 PT PT107852899T patent/PT2504332E/pt unknown
- 2010-11-24 EA EA201270646A patent/EA023923B1/ru not_active IP Right Cessation
- 2010-11-24 DK DK14164650.5T patent/DK2796457T3/en active
- 2010-11-24 MY MYPI2019004988A patent/MY192644A/en unknown
- 2010-11-24 SG SG10201407881WA patent/SG10201407881WA/en unknown
- 2010-11-24 HU HUE16175117A patent/HUE045784T2/hu unknown
- 2010-11-24 UA UAA201207602A patent/UA113491C2/uk unknown
- 2010-11-24 EA EA201890254A patent/EA201890254A3/ru unknown
- 2010-11-24 IL IL310635A patent/IL310635A/en unknown
- 2010-11-24 NZ NZ600155A patent/NZ600155A/en unknown
- 2010-11-24 NZ NZ625712A patent/NZ625712A/en unknown
- 2010-11-24 WO PCT/US2010/057952 patent/WO2011066352A1/fr active Application Filing
- 2010-11-24 PL PL19182732T patent/PL3599237T3/pl unknown
- 2010-11-24 ES ES19182732T patent/ES2875382T3/es active Active
- 2010-11-24 TW TW099140523A patent/TWI586663B/zh active
- 2010-11-24 BR BR112012012947A patent/BR112012012947B8/pt active IP Right Grant
- 2010-11-24 CN CN202010962639.3A patent/CN112521366A/zh active Pending
- 2010-11-24 US US13/511,768 patent/US11458119B2/en active Active
- 2010-11-24 CN CN201080061535.XA patent/CN102712629B/zh active Active
-
2012
- 2012-05-18 TN TNP2012000237A patent/TN2012000237A1/en unknown
- 2012-05-20 IL IL219892A patent/IL219892A0/en unknown
- 2012-05-23 DO DO2012000141A patent/DOP2012000141A/es unknown
- 2012-05-24 CL CL2012001348A patent/CL2012001348A1/es unknown
- 2012-05-24 NI NI201200096A patent/NI201200096A/es unknown
- 2012-05-24 CR CR20120277A patent/CR20120277A/es unknown
- 2012-05-24 EC ECSP12011926 patent/ECSP12011926A/es unknown
- 2012-05-25 GT GT201200161A patent/GT201200161A/es unknown
- 2012-06-20 MA MA34989A patent/MA33838B1/fr unknown
- 2012-12-14 HK HK15103822.1A patent/HK1203485A1/zh unknown
- 2012-12-14 HK HK12112977.8A patent/HK1172031A1/xx unknown
-
2014
- 2014-08-18 HR HRP20140780TT patent/HRP20140780T4/hr unknown
- 2014-08-28 CY CY20141100690T patent/CY1115880T1/el unknown
-
2015
- 2015-07-06 JP JP2015134942A patent/JP6370264B2/ja active Active
- 2015-11-02 PH PH12015502514A patent/PH12015502514A1/en unknown
-
2016
- 2016-01-13 US US14/994,489 patent/US20160120842A1/en not_active Abandoned
- 2016-02-22 US US15/049,946 patent/US10888547B2/en active Active
- 2016-03-04 JP JP2016041843A patent/JP6452635B2/ja active Active
- 2016-04-22 AU AU2016202591A patent/AU2016202591B2/en active Active
- 2016-08-11 SM SM201600273T patent/SMT201600273B/it unknown
- 2016-08-17 HR HRP20161038TT patent/HRP20161038T1/hr unknown
- 2016-08-17 CY CY20161100807T patent/CY1117996T1/el unknown
- 2016-09-19 DO DO2016000250A patent/DOP2016000250A/es unknown
- 2016-10-12 CL CL2016002589A patent/CL2016002589A1/es unknown
-
2017
- 2017-11-27 AU AU2017265180A patent/AU2017265180B2/en active Active
-
2018
- 2018-06-27 IL IL260299A patent/IL260299A/en unknown
- 2018-08-23 EC ECSENADI201863798A patent/ECSP18063798A/es unknown
- 2018-09-07 JP JP2018167432A patent/JP7150528B2/ja active Active
-
2019
- 2019-09-12 HR HRP20191647 patent/HRP20191647T1/hr unknown
- 2019-11-13 CY CY20191101196T patent/CY1122698T1/el unknown
-
2020
- 2020-08-14 JP JP2020136889A patent/JP2020189873A/ja active Pending
-
2021
- 2021-01-07 US US17/143,821 patent/US20210369672A1/en active Pending
- 2021-03-18 AR ARP210100683A patent/AR121612A2/es unknown
- 2021-03-18 AR ARP210100682A patent/AR121611A2/es unknown
- 2021-06-13 IL IL283935A patent/IL283935A/en unknown
- 2021-09-03 US US17/465,994 patent/US20210393590A1/en not_active Abandoned
-
2022
- 2022-07-14 US US17/865,195 patent/US20230172903A1/en active Pending
-
2023
- 2023-06-21 JP JP2023101301A patent/JP2023116764A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL283935A (en) | Crystalline and amorphous form of genz 112638 hemitartrate as an inhibitor of glucosylceramide synthase | |
HK1254977A1 (zh) | 索非布韋(sofosbuvir)的結晶形式 | |
HK1200440A1 (zh) | 種抑制劑的結晶形式 | |
HRP20170214T1 (hr) | Amorfna sol makrocikličkog inhibitora hcv | |
IL210322A0 (en) | Crystalline salts of sitagliptin | |
EP2421867A4 (fr) | Inhibiteurs pipéridiniques de la janus kinase 3 | |
LT2155200T (lt) | Karbamoil-cikloheksano darinio kristalinė forma | |
PT2611779T (pt) | Formas cristalinas de um inibidor do fator xa | |
IL221198A0 (en) | Crystalline salts of a potent hcv inhibitor | |
HK1169408A1 (en) | Cdk inhibitor salts cdk | |
SI2358676T1 (sl) | Kristalinična oblika 4-(2-(2-fluorofenoksimetil)fenil)piperidinske spojine | |
PT2439202T (pt) | Compostos inibidores de 11-beta-hidroxiesteroide desidrogenase tipo 1 | |
ZA201104319B (en) | Crystalline forms of a 3-carboxypropyl-aminotetralin compound | |
HK1175780A1 (en) | Crystalline cdc7 inhibitor salts cdc7 | |
HK1177459A1 (zh) | 因子抑制劑的結晶鹽 | |
AP2717A (en) | Mono-hydrochloric salts of an inhibitor of histonedeacetylase | |
HUP0800755A2 (en) | Crystalline forms of rosiglitazone | |
EP2488530A4 (fr) | Inhibiteurs de la rénine | |
EP2482821A4 (fr) | Sels de chlorhydrate cristallins d'inhibiteurs de kinase c-met |